SGLT2 Inhibitors in Type 1 Diabetes – Where Do We Stand in 2025?
Zehra Haider, M.D. Assistant Professor of Medicine & Pediatrics, Barbara Davis Center for Diabetes - University of Colorado Anschutz Zehra Haider, M.D. Assistant Professor of Medicine & Pediatrics, Barbara Davis Center for Diabetes - University of Colorado Anschutz

SGLT2 Inhibitors in Type 1 Diabetes – Where Do We Stand in 2025?

SGLT2 inhibitors have dramatically advanced the management of type 2 diabetes by reducing glycemia, cardiovascular events, and renal disease progression.

Read More